SCHEMBL7206509

SCHEMBL7206509

NC(=O)N1CCC(S(=O)(=O)c2ccc(OCc3ccccc3F)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 8/20 0.45
MMP1 P03956 7/20 0.45
ADAM17 P78536 2/20 0.45
MMP13 P45452 5/20 0.45
ADAMTS4 O75173 4/20 0.45
MAOB P27338 2/20 0.44
PARP15 Q460N3 1/20 0.44
PARP14 Q460N5 1/20 0.44
PARP10 Q53GL7 1/20 0.44
KCNH2 Q12809 5/20 0.44
SCN1A P35498 1/20 0.43
SCN4A P35499 1/20 0.43
SCN7A Q01118 1/20 0.43
SCN5A Q14524 1/20 0.43
SCN9A Q15858 1/20 0.43
SCN2A Q99250 1/20 0.43
SCN8A Q9UQD0 1/20 0.43
SCN10A Q9Y5Y9 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2B6 P20813 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7208181 0.89 MMP13 (0.56) MMP1ADAM17MMP13ADAMTS4MAOB
SCHEMBL7202626 0.89 MMP1 (0.57) MMP1ADAM17MMP13ADAMTS4
SCHEMBL7203984 0.88 MMP1 (0.45) MMP1ADAM17MMP13ADAMTS4PARP10
SCHEMBL7206504 0.88 MMP1 (0.47) MMP1ADAM17MMP13ADAMTS4PARP14
SCHEMBL7205420 0.85 MMP1 (0.45) MMP1ADAM17MMP13ADAMTS4MAOB
SCHEMBL7199674 0.84 MMP1 (0.42) MMP1MMP13PARP10
SCHEMBL7201593 0.84 MAOB (0.49) MMP1ADAM17MMP13MAOBPARP10
SCHEMBL7201292 0.84 PARP10 (0.44) MMP1MMP13ADAMTS4PARP10
SCHEMBL7207163 0.83 MMP1 (0.45) MMP1MMP13PARP14PARP10NPC1
SCHEMBL7205273 0.82 MMP1 (0.56) MMP1ADAM17MMP13ADAMTS4MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 SCN3A 3001/4885MMP1 8/4885ADAM17 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.